What is HC Wainwright’s Estimate for BiomX FY2025 Earnings?

BiomX Inc. (NYSEAMERICAN:PHGE) – HC Wainwright upped their FY2025 EPS estimates for BiomX in a report released on Tuesday, November 25th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($19.80) per share for the year, up from their prior forecast of ($22.43). HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for BiomX’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for BiomX’s Q4 2025 earnings at ($4.61) EPS, FY2026 earnings at ($5.85) EPS, FY2027 earnings at ($6.01) EPS and FY2028 earnings at ($4.57) EPS.

BiomX Stock Performance

Shares of BiomX stock opened at $4.70 on Thursday. BiomX has a fifty-two week low of $4.66 and a fifty-two week high of $22.06. The company has a market capitalization of $7.19 million, a P/E ratio of -0.18 and a beta of 1.46. The company has a fifty day moving average of $9.13 and a 200 day moving average of $9.16.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).